The Triple G 100mg: Complete Research & Safety Guide

What Is The Triple G 100mg?

The Triple G 100mg is a research product name associated with retatrutide-related peptide research. Retatrutide, also known as LY3437943, is an investigational single peptide designed to activate three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This three-receptor activity is why retatrutide is commonly described as a “triple agonist.”

The “100mg” designation refers to the labeled amount of material in the particular commercial product. It should not be confused with the milligram doses evaluated in clinical trials. Clinical studies of retatrutide have investigated substantially smaller doses, including 4mg, 9mg and 12mg in a 2026 phase 3 diabetes study.

Because commercial research products can differ in formulation, concentration and labeling, researchers should verify the exact composition and quantity using the manufacturer’s documentation and batch-specific Certificate of Analysis.

Triple-Receptor Research

The scientific interest surrounding The Triple G 100mg comes from research into retatrutide’s interaction with three metabolic hormone receptors. GIP and GLP-1 are involved in glucose-regulation and nutrient-related signaling, while glucagon has important roles in energy metabolism.

Rather than acting through only one receptor pathway, retatrutide was developed to combine activity at all three. This mechanism has been investigated in clinical studies involving obesity and type 2 diabetes. Earlier phase 2 research demonstrated dose-dependent changes in body weight and glycemic measures, while also documenting gastrointestinal adverse events in some participants.

These clinical findings apply to the investigational drug studied in controlled clinical trials and should not automatically be applied to an independently manufactured or commercially labeled product such as The Triple G 100mg.

What Research Has Found

Retatrutide has progressed through multiple stages of clinical investigation. A phase 2 study published in the New England Journal of Medicine evaluated retatrutide in adults with obesity and found substantial reductions in body weight at the studied doses over 48 weeks. The study also examined adverse events and other metabolic outcomes.

More recently, a 2026 phase 3 trial in adults with inadequately controlled type 2 diabetes evaluated 4mg, 9mg and 12mg retatrutide doses. The trial reported improvements in HbA1c and body weight compared with placebo, while gastrointestinal events were among the most frequently reported adverse events.

These results are scientifically relevant to understanding retatrutide research, but they do not establish that a 100mg commercial research product has the same characteristics, purity or clinical properties as the material used in those trials.

Product Specifications

The exact specifications of The Triple G 100mg should be confirmed from the product documentation. Important information may include:

• Product name: The Triple G 100mg
• Research compound: Verify whether the product contains retatrutide/LY3437943
• Labeled quantity: 100mg
• Physical form: Verify whether supplied as a lyophilized research peptide
• Batch or lot number
• Purity specification
• Identity testing
• Certificate of Analysis
• Manufacturer or supplier information

A batch-specific Certificate of Analysis is particularly useful because it can provide information about the actual material supplied. Researchers should not assume that the specifications of one batch apply to another.

Storage Considerations

The Triple G 100mg should be stored according to the manufacturer’s instructions. Research peptides may require controlled storage conditions to help preserve their physical and chemical characteristics.

Researchers should keep the original container appropriately labeled and protected from conditions that could compromise the material. Excessive heat, moisture, light exposure and repeated unnecessary handling may affect laboratory materials depending on their formulation and packaging.

The manufacturer’s documentation should always take priority over generic peptide-storage advice.

Research Applications

The Triple G 100mg may be relevant to laboratory research involving peptide characterization, receptor signaling, metabolic pathways and experimental studies of GIP, GLP-1 and glucagon receptor activity.

Retatrutide research is particularly focused on understanding how simultaneous activation of these three pathways affects metabolic regulation. Current clinical development includes investigations involving type 2 diabetes, obesity and related conditions.

Researchers should distinguish between evidence obtained from controlled clinical trials of pharmaceutical-grade investigational retatrutide and evidence concerning a commercially supplied research product. Product-specific analytical testing remains important when evaluating any research material.

Quality and Documentation

When assessing The Triple G 100mg, researchers should look for clear product identification, a batch number, labeled quantity and supporting analytical documentation.

Where available, a Certificate of Analysis may provide information about purity and identity testing. Analytical techniques such as HPLC and mass spectrometry can be useful for characterizing peptide materials, although the precise testing performed depends on the manufacturer and laboratory.

Documentation should be reviewed for the specific batch being evaluated rather than relying solely on general statements made on a product page.

Safety and Regulatory Considerations

Retatrutide remains an investigational medication and is not currently FDA-approved for public use. Lilly states that retatrutide is being studied in phase 3 clinical trials and that its safety and efficacy continue to be evaluated.

Clinical research has reported adverse events, with gastrointestinal effects among those commonly observed in retatrutide studies. The 2026 phase 3 diabetes trial also reported adverse-event-related discontinuations in some participants.

These findings should not be interpreted as establishing the safety of The Triple G 100mg specifically. A commercially labeled research product may differ from the investigational material used in clinical trials.

Summary

The Triple G 100mg is a research product name associated with retatrutide-related triple-receptor research. Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors and has been evaluated in phase 2 and phase 3 clinical research.

The 100mg product quantity should be treated as a commercial product specification rather than a clinical dosing reference. Researchers should verify the exact formulation, identity, purity, batch information and Certificate of Analysis before evaluating the material.